New perspectives in human stem cell therapeutic research by Trounson Alan

“…The active participation of governments, academia, biotechnology, pharmaceutical companies, and private investment is a powerful consortium for advances in health.…”
Get full text

Identifying placebo responders and predictors of response in osteoarthritis: a protocol for individual patient data meta-analysis by Yu Fu, Monica S. M. Persson, Archan Bhattacharya, Siew-Li Goh, Joanne Stocks, Marienke van Middelkoop, Sita M. A. Bierma-Zeinstra, David Walsh, Michael Doherty, Weiya Zhang

“…The results of this study may also be useful for pharmaceutical companies, who could improve the design of their studies in order to separate the specific treatment from the non-specific contextual (i.e. placebo) effects. …”
Get full text

Modern Problems of Antibiotic Therapy in Ophthalmology and the Perspective Ways of Solution. Literature Review by V. O. Ponomarev, V. N. Kazaykin, O. P. Ponomarev

“…A number of preventive measures that could significantly affect the crisis of antibiotic resistance are being actively worked out at the state level and include programs to reduce the free circulation of antibiotics, optimize therapeutic regimes, improve diagnostic measures for the verification of pathogens, prevent the spread of infections, optimize interaction between pharmaceutical companies and registration organizations, stimulate investment and public-private partnership, and of course the international initiative on systemic interaction. …”
Get full text

Impact of a multifaceted intervention on physicians’ knowledge, attitudes and practices in relation to pharmaceutical incentivisation: protocol for a randomised control trial by Afifah Rahman-Shepherd, Mishal Khan, Iqbal Azam, Sadia Shakoor, Amna Rehana Siddiqui, Rumina Hasan, Muhammad Naveed Noor, Sabeen Sharif Khan

“…In their interactions with pharmaceutical companies, private general practitioners (GPs) can experience the conflict of interest (COI), a situation whereby the impartiality of GPs’ professional decision making may be influenced by secondary interests such as financial gains from prescribing specific pharmaceutical brands.Methods and analysis This study is a randomised controlled trial to assess the impact of a multifaceted intervention on GPs’ medical practice. …”
Get full text

The Effect of Financial Risk Taking on Profitability in the Pharmaceutical Industry by Gergő Tömöri, Vilmos Lakatos, Bernadett Béresné Mártha

“…This paper examined one possible means of covering the extremely high indirect costs (R&D, marketing) of pharmaceutical companies, also justified by the restructuring of the industry and the effect of investments in long term financial instruments on the ROE of the same business entities. …”
Get full text

The Spicy Story of Cannabimimetic Indoles by Allyn C. Howlett, Brian F. Thomas, John W. Huffman

“…The distribution to the public of potent alkyl indole synthetic cannabimimetic chemicals without regard for consumer safety contrasts with the adherence to regulatory requirements for demonstration of safety that are routinely observed by ethical pharmaceutical companies that market medicines.…”
Get full text

Integrating traditional Chinese (herbal) medicines into risk based regulation - With focus on non-clinical requirements to demonstrate safety by Vivian S.W. Chan Fung

“…With Hong Kong (China) conducting ‘first hand’ review for eligible pCm, it provides an option for overseas and local pharmaceutical companies to register their products in Hong Kong (China) without the need to rely on issuance of Certificate of Pharmaceutical Product from other countries. …”
Get full text

Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals. by Jing Hao, Rosa Rodriguez-Monguio, Enrique Seoane-Vazquez

“…Non-NME-FDC added a median of 9.70 (2.75, 16.24) years to the patent and exclusivity life of the single active ingredients in the combination.FDC approvals significantly increased over the last twenty years. Pharmaceutical companies market FDC drugs shortly before the generic versions of the single ingredients enter the market extending the patent and exclusivity life of drugs included in the combination.…”
Get full text

Profitability and Market Value of Orphan Drug Companies: A Retrospective, Propensity-Matched Case-Control Study. by Dyfrig A Hughes, Jannine Poletti-Hughes

“…For each additional orphan drug sold, return on assets increased by 11.1% (0.6% to 21.3%), Tobin's Q by 2.7% (0.2% to 5.2%), and market to book value ratio by 5.8% (0.7% to 10.9%).Publicly listed pharmaceutical companies that are orphan drug market authorization holders are associated with higher market value and greater profits than companies not producing treatments for rare diseases.…”
Get full text

Aducanumab and lecanemab – two novel antibodies against pathologic species of amyloid beta in the treatment of Alzheimer’s disease by Jakub Wojcieszak

“…Despite the considerable efforts of the scientific community and pharmaceutical companies, no new drug against AD has been registered over the last decades. …”
Get full text

ENFORCEMENT STATUS OF THE POISON ACT 1952 AGAINST OFFENCES RELATED TO KRATOM (MITRAGYNA SPECIOSA KORTH) MISUSE IN MALAYSIA by Samihah Khalil@Halim, Siti Alida John Abdullah, Rusniah Ahmad

“…In pharmacology, there is research and development demand for kratom, and demands from international pharmaceutical companies for kratom had created illegal rational economic exploitation of Malaysia’s kratom by individuals, so to speak resulting in more intricacies to existing complication. …”
Get full text

World practice of providing scientific advice on the development and authorisation of innovative medicines by E. V. Melnikova, O. V. Merkulova, V. A. Merkulov

“…However, the inability to accurately predict the efficacy and financial rewards of such medicines for pharmaceutical companies, as well as significant labour and financial costs associated with their development and clinical use, hinder their entry into the market. …”
Get full text

Influence of Sales Promotion Techniques on Consumers’ Purchasing Decisions at Community Pharmacies by Younes Ben Said, Nicola Luigi Bragazzi, Natalia Valeryevna Pyatigorskaya

“…This research aims to identify the most prevalent and impactful sales promotion tools used by pharmaceutical companies on consumers’ purchasing decisions at community pharmacies. …”
Get full text

Understanding Public Perceptions of the HPV Vaccination Based on Online Comments to Canadian News Articles. by Yael Feinberg, Jennifer A Pereira, Susan Quach, Jeffrey C Kwong, Natasha S Crowcroft, Sarah E Wilson, Maryse Guay, Yang Lei, Shelley L Deeks, Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) Program Delivery and Evaluation Group

“…Common themes in negative comments included concerns regarding HPV vaccine safety and efficacy, distrust of pharmaceutical companies and government, and belief that school-age children are too young for HPV vaccine. …”
Get full text

ENFORCEMENT STATUS OF THE POISON ACT 1952 AGAINST OFFENCES RELATED TO KRATOM (MITRAGYNA SPECIOSA KORTH) MISUSE IN MALAYSIA by Samihah Khalil@Halim, Siti Alida John Abdullah, Rusniah Ahmad

“…In pharmacology, there is research and development demand for kratom, and demands from international pharmaceutical companies for kratom had created illegal rational economic exploitation of Malaysia’s kratom by individuals, so to speak resulting in more intricacies to existing complication. …”
Get full text

A short review on CRP synthesis inhibition in cardiovascular disease by Myron Zaczkiewicz, Oliver Zimmermann, Jan Torzewski

“…Because of patent law considerations, however, pharmaceutical companies had limited interest in further pursuing this possible path. …”
Get full text

The Biological Activity of Natural Alkaloids against Herbivores, Cancerous Cells and Pathogens by Amin Thawabteh, Salma Juma, Mariam Bader, Donia Karaman, Laura Scrano, Sabino A. Bufo, Rafik Karaman

“…The unique properties of these secondary metabolites are the main reason for their utilization by the pharmaceutical companies for the treatment of different diseases. …”
Get full text

Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature. by Elizabeth J J Berm, Margot de Looff, Bob Wilffert, Cornelis Boersma, Lieven Annemans, Stefan Vegter, Job F M van Boven, Maarten J Postma

“…Since 2010, more studies were funded by pharmaceutical companies. Most recent studies performed cost-utility analysis, univariate and probabilistic sensitivity analyses, and discussed limitations of their economic evaluations. …”
Get full text

Modern Approaches in the Discovery and Development of Plant-Based Natural Products and Their Analogues as Potential Therapeutic Agents by Asim Najmi, Sadique A. Javed, Mohammed Al Bratty, Hassan A. Alhazmi

“…In the past few decades, pharmaceutical companies demonstrated insignificant attention towards natural product drug discovery, mainly due to its intrinsic complexity. …”
Get full text

A Quantitative Analysis of Undisclosed Conflicts of Interest in Pharmacology Textbooks. by Brian J Piper, Hassenet M Telku, Drew A Lambert

“…The goal of this investigation was to determine whether the authors of pharmacology textbooks have undisclosed financial CoIs and to identify author characteristics associated with CoIs.The presence of potential CoIs was evaluated by submitting author names (N = 403; 36.3% female) to a patent database (Google Scholar) as well as a database that reports on the compensation ($USD) received from 15 pharmaceutical companies (ProPublica's Dollars for Docs). All publications (N = 410) of the ten highest compensated authors from 2009 to 2013 and indexed in Pubmed were also examined for disclosure of additional companies that the authors received research support, consulted, or served on speaker's bureaus. …”
Get full text